Evidence map›Paper›PMID 37737889›Full record

ArticleAdvances in therapy2023

The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases.

Darmendra Ramcharran, Bruce Strober, Kenneth Gordon, Cynthia DeKlotz, Steven Fakharzadeh, Ya-Wen Yang, Joel Swerdel, Jill Hardin, Sridhar Dronavalli, Amy S Paller

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Ethnic Differences of Palmoplantar Pustulosis: A Systematic Review.American journal of clinical dermatology · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Darmendra RamcharranGlobal Research and Development Epidemiology, Janssen Pharmaceutical Companies of Johnson and Johnson, Titusville, NJ, USA.
Bruce StroberYale University, New Haven, CT, USA.
Kenneth GordonMedical College of Wisconsin, Milwaukee, WI, USA.
Cynthia DeKlotzImmunology Research and Development, Janssen Pharmaceutical Companies of Johnson and Johnson, Springhouse, PA, USA.
Steven FakharzadehImmunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson and Johnson, Horsham, PA, USA.
Ya-Wen YangImmunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson and Johnson, Horsham, PA, USA.
Joel SwerdelJanssen Research and Development, Titusville, NJ, USA.
Jill HardinJanssen Research and Development, Titusville, NJ, USA.
Sridhar DronavalliAtlanta Center for Dermatologic Diseases, Atlanta, GA, USA.
Amy S PallerDepartment of Dermatology, Northwestern University Feinberg School of Medicine and the Ann and Robert H Lurie Children's Hospital, 676 N. St. Clair, Suite 1600, Chicago, IL, 60611-2997, USA. apaller@northwestern.edu.
Janssen (United States) · USCentral Dermatology · USJohnson & Johnson (United States) · USMedical College of Wisconsin · USNorthwestern Memorial Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPalmoplantar pustulosis (PPP) is a chronic inflammatory condition characterized by sterile pustules on the palms and soles. This study evaluated the epidemiology of PPP using claims and electronic health record (EHR) databases.

methodsPatients coded for PPP in the United States (US) and Japan from 2016 to 2020 were identified. Several PPP definitions were evaluated; the specific definition (≥ 2 visits coded for PPP, the second 31-730 days after diagnosis) was chosen for characterizing PPP epidemiology. Baseline characteristics and pre- and post-diagnosis treatments were summarized. Prevalence and incidence rates were analyzed by calendar year, sex, age, and database.

resultsPrevalence and incidence of PPP were higher in Japan than the US. PPP prevalence increased over time. PPP occurred predominantly in adulthood and was more common among women. Features of metabolic syndromes, anxiety, and depression were more common among US PPP patients. Consistently high baseline use of anti-bacterial, anti-inflammatory/anti-rheumatic, and obstructive airway disease treatments was observed among PPP patients. Potential miscoding or misclassification of PPP limited this analysis. Prevalence estimates from databases may differ from field- and population-based approaches.

conclusionsThe burden of PPP was greater in Japan than in the US. Additional studies are needed to further elucidate PPP epidemiology worldwide.

Indexed as

Electronic Health RecordsPsoriasisAcute DiseaseChronic DiseaseFemaleHumansInsurance, HealthEpidemiologyIncidenceJapanPalmoplantar pustulosisPrevalenceUnited States

Identifiers

PMID37737889
PMCPMC10567878
OpenAlexW4386944066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.